Functional Medicine in Asthma (FAst) Study

Completed · Not applicable

Conditions studied: Asthma

In brief

This is a pilot, proof of concept, early stage study. The study goal is to determine whether the Functional Medicine approach to the treatment of moderate to severe persistent asthma enhances standard guideline-based care with respect to asthma outcomes.

Key facts

Study ID

NCT02808689

Run by

The Cleveland Clinic

People needed

48

Starts

2016-09-01

Expected to finish

2021-02-01

Last updated by the study team

2021-04-01

Who can join

Age: 19 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Women and men with ages >18 and <65
• Nonsmokers or Former smokers quit >1 yr ago, with 15 pack-years or less history of smoking
• Clinical history consistent with moderate to severe asthma
• Measures of airflow obstruction and reactivity consistent with asthma (12% BD response and/or positive methacholine challenge test) historically or at initial/screening visit FEV1 between 40-100% predicted post bronchodilator
• Uncontrolled Asthma categorized ACT ≤19 (i.e. Not well controlled ACT= 16-19, Very Poorly Controlled ACT ≤ 15)
• Willing to be seen in Asthma Center and willing to consider Functional Medicine approach as an add-on to Asthma Center care
• Able to attend study visits as outlined in protocol.

You may not qualify if…

• Current smoker
• Life threatening asthma defined as 2 or more intubations for asthma in last 12 months
• Major psychiatric disturbance
• Any disorder, including but not limited to gastrointestinal, renal, neurological, infectious, endocrine, metabolic or other physical impairment, that is not stable in the opinion of the investigator
• Clinically important pulmonary disease other than asthma, including but not limited to COPD, pulmonary fibrosis, cystic fibrosis, bronchiectasis
• Pregnant or breastfeeding
• Controlled asthma defined by stability and by ACT >19 and physician discretion for 2-3 months
• Current asthma exacerbations, (exacerbations are defined by urgent visit for asthma, hospitalization or ICU stay for asthma, 3 days in succession of doubling use of SABA or need for systemic steroids if not on systemic steroids, or increase of systemic steroids if normally on systemic steroid) (patient can be rescreened 4 weeks after exacerbation has resolved)
• Stable lung function, reduction in no more than 20% (or clinically significant per patient) reduction of pulmonary function testing from time of stability
• History of being seen or had intervention/care based upon evaluation in Functional Medicine Institute or following Functional Medicine principles/ approach to asthma care.

Where it is running

• The Cleveland Clinic Foundation — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.